| abstract |
FLAP inhibitor 3- [3-tert-butyl-sulfanyl-1- [4- (6-ethoxy-pyridin-3-yl) -benzyl] -5- (5-methyl-pyridin-2-ylmethoxy) -1 H -indol-2-yl] -2,2-dimethyl-propionic acid or a pharmaceutically acceptable salt thereof is described herein. Also disclosed are methods for the production of FLAP inhibitors, or pharmaceutically acceptable salts thereof, including solvates and polymorphs thereof. Also provided is a pharmaceutical composition suitable for administration to a mammal, including a FLAP inhibitor, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for the treatment of such leukotriene-dependent or leukotriene mediated diseases or conditions, A method of using the composition is described. |